Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAS in Barrett's Esophagus as Future Biomarkers for Dysplasia and Cancer
NCT02879721Phase 1Completed
- Sponsor
- University of Gothenburg
- Start
- Oct 2009
- Primary completion
- Dec 2012
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of candesartan and enalapril in Barrett's esophagus (3 arms), sponsored by University of Gothenburg. Primary endpoint: Change in expression of proteins associated with inflammation, proliferation and cancer development at 3 weeks. Started Oct 2009; status: completed.
02
Drugs
candesartanenalapril
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT02879721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879721.